Arovella Therapeutics Limited (ALA.AX)
AUD 0.08
(1.25%)
AUD 0.08
(1.25%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -8.83 Million AUD | 14.84% |
| 2023 | -10.37 Million AUD | -25.6% |
| 2022 | -7.87 Million AUD | -127.08% |
| 2021 | -4.99 Million AUD | 8.9% |
| 2020 | -3.4 Million AUD | -84.28% |
| 2019 | -8.12 Million AUD | 68.61% |
| 2018 | -6.44 Million AUD | -249.67% |
| 2017 | -1.82 Million AUD | 37.01% |
| 2016 | -2.72 Million AUD | 28.99% |
| 2015 | -3.69 Million AUD | -90.95% |
| 2014 | -2.01 Million AUD | -16.48% |
| 2013 | -1.74 Million AUD | -9.75% |
| 2012 | -4.62 Million AUD | 43.97% |
| 2011 | -4.17 Million AUD | -39.56% |
| 2010 | -4.41 Million AUD | 14.1% |
| 2009 | -2.79 Million AUD | -3.09% |
| 2008 | -8.57 Million AUD | -110.88% |
| 2007 | -1.33 Million AUD | -793.06% |
| 2006 | 425.26 Thousand AUD | 111.41% |
| 2005 | -1.33 Million AUD | -154.12% |
| 2004 | -525.03 Thousand AUD | 40.13% |
| 2003 | -876.93 Thousand AUD | -16.92% |
| 2002 | -750 Thousand AUD | -766.55% |
| 2001 | -86.55 Thousand AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.93 Million AUD | -192.87% |
| 2024 Q3 | -2.41 Million AUD | 58.75% |
| 2024 FY | - AUD | -21.76% |
| 2024 Q4 | -2.41 Million AUD | 0.0% |
| 2024 Q1 | -2 Million AUD | 67.58% |
| 2023 Q3 | -2.36 Million AUD | 43.59% |
| 2023 Q2 | -4.2 Million AUD | -166.55% |
| 2023 Q1 | -1.57 Million AUD | 55.71% |
| 2023 FY | - AUD | -25.6% |
| 2023 Q4 | -4.64 Million AUD | -95.93% |
| 2022 Q3 | -1.89 Million AUD | 45.57% |
| 2022 Q4 | -3.55 Million AUD | -87.46% |
| 2022 FY | - AUD | -127.08% |
| 2022 Q1 | -1.83 Million AUD | 23.75% |
| 2022 Q2 | -3.48 Million AUD | -90.3% |
| 2021 Q2 | -1.63 Million AUD | -87.31% |
| 2021 Q3 | -1.03 Million AUD | 36.53% |
| 2021 Q4 | -2.4 Million AUD | -131.98% |
| 2021 FY | - AUD | 8.9% |
| 2021 Q1 | -871.48 Thousand AUD | 62.23% |
| 2020 FY | - AUD | -84.28% |
| 2020 Q2 | -1.93 Million AUD | -84.65% |
| 2020 Q1 | -1.05 Million AUD | 21.5% |
| 2020 Q3 | -1.27 Million AUD | 34.34% |
| 2020 Q4 | -2.3 Million AUD | -81.2% |
| 2019 Q3 | -756.29 Thousand AUD | -111.64% |
| 2019 Q2 | -357.35 Thousand AUD | 0.0% |
| 2019 Q1 | -357.35 Thousand AUD | 45.14% |
| 2019 Q4 | -1.33 Million AUD | -76.9% |
| 2019 FY | - AUD | 68.61% |
| 2018 Q4 | -651.35 Thousand AUD | -0.39% |
| 2018 Q2 | -1.03 Million AUD | 0.0% |
| 2018 FY | - AUD | -249.67% |
| 2018 Q1 | -1.03 Million AUD | -109.12% |
| 2018 Q3 | -648.82 Thousand AUD | 37.52% |
| 2017 Q4 | -496.55 Thousand AUD | -27.55% |
| 2017 FY | - AUD | 37.01% |
| 2017 Q3 | -389.29 Thousand AUD | 19.45% |
| 2017 Q2 | -483.28 Thousand AUD | -0.0% |
| 2017 Q1 | -483.28 Thousand AUD | 16.06% |
| 2016 Q1 | -827.54 Thousand AUD | 7.05% |
| 2016 FY | - AUD | 28.99% |
| 2016 Q4 | -575.74 Thousand AUD | 0.0% |
| 2016 Q2 | -827.54 Thousand AUD | 0.0% |
| 2016 Q3 | -575.74 Thousand AUD | 30.43% |
| 2015 FY | - AUD | -90.95% |
| 2015 Q4 | -890.3 Thousand AUD | 0.0% |
| 2015 Q3 | -890.3 Thousand AUD | 5.54% |
| 2015 Q2 | -942.51 Thousand AUD | -0.0% |
| 2015 Q1 | -942.51 Thousand AUD | -19.46% |
| 2014 Q2 | -124.61 Thousand AUD | -0.0% |
| 2014 Q1 | -124.61 Thousand AUD | 69.91% |
| 2014 FY | - AUD | -16.48% |
| 2014 Q4 | -788.95 Thousand AUD | 0.0% |
| 2014 Q3 | -788.95 Thousand AUD | -533.09% |
| 2013 Q1 | -458.27 Thousand AUD | 0.0% |
| 2013 Q3 | -414.15 Thousand AUD | 9.63% |
| 2013 Q4 | -414.15 Thousand AUD | 0.0% |
| 2013 FY | - AUD | -9.75% |
| 2013 Q2 | -458.27 Thousand AUD | 0.0% |
| 2012 FY | - AUD | 43.97% |
| 2011 FY | - AUD | -39.56% |
| 2010 FY | - AUD | 14.1% |
| 2009 FY | - AUD | -3.09% |
| 2008 FY | - AUD | -110.88% |
| 2007 FY | - AUD | -793.06% |
| 2006 FY | - AUD | 111.41% |
| 2005 FY | - AUD | -154.12% |
| 2004 FY | - AUD | 40.13% |
| 2003 FY | - AUD | -16.92% |
| 2002 FY | - AUD | -766.55% |
| 2001 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AdAlta Limited | -5.3 Million AUD | -66.579% |
| Acrux Limited | -7.93 Million AUD | -11.375% |
| Race Oncology Limited | -14.2 Million AUD | 37.809% |
| Biome Australia Limited | -1.57 Million AUD | -459.68% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 36.541% |
| BTC Health Limited | 1.05 Million AUD | 937.039% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 21.829% |
| CSL Limited | 4.73 Billion AUD | 100.187% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 80.216% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 117.032% |
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 185.135% |
| Hexima Limited | -995.54 Thousand AUD | -787.271% |
| Immutep Limited | -42.87 Million AUD | 79.398% |
| Memphasys Limited | -3.3 Million AUD | -167.047% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 104.433% |
| Noxopharm Limited | -5.94 Million AUD | -48.569% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -22.927% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 80.533% |
| Starpharma Holdings Limited | -12.57 Million AUD | 29.767% |
| Tissue Repair Ltd | -5.77 Million AUD | -52.955% |
| Biotron Limited | -5.04 Million AUD | -75.259% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 54.867% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -506.397% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -196.914% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 75.761% |
| Patrys Limited | -3.49 Million AUD | -152.943% |
| Orthocell Limited | -11.68 Million AUD | 24.381% |
| Imugene Limited | -147.97 Million AUD | 94.031% |
| PYC Therapeutics Limited | -38.11 Million AUD | 76.827% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | -11.992% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 11.226% |
| Nanollose Limited | -1.14 Million AUD | -669.505% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -1126.077% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -391.746% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -93.727% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -213.442% |
| Nyrada Inc. | -4.59 Million AUD | -92.184% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 138.462% |
| Dimerix Limited | -24.95 Million AUD | 64.609% |
| PharmAust Limited | -9.45 Million AUD | 6.544% |
| AnteoTech Limited | -11.57 Million AUD | 23.661% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 86.313% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 58.635% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -172.417% |
| Actinogen Medical Limited | -12.92 Million AUD | 31.638% |
| Immuron Limited | -6.19 Million AUD | -42.646% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -365.493% |